TY - JOUR
T1 - Treatment of Locally Advanced Nasopharyngeal Carcinoma by Helical Tomotherapy
T2 - An Observational, Prospective Analysis
AU - Liu, Zhigang
AU - Xu, Chenyang
AU - Jiang, Rong
AU - Liu, Guiyun
AU - Liu, Qiaodan
AU - Zhou, Jiao
AU - Liu, Fengxin
AU - Yao, Jijin
AU - Wang, Siyang
AU - Jiang, Wen
N1 - Funding Information:
This work was supported by National Natural Science Foundation of China [grant number 81572500 ], Hunan Young Talents [grant number 2016RS3036 ], and Hunan Provincial Health Planning Commission Project [grant number C20180450 ].
Publisher Copyright:
© 2019 The Authors
PY - 2019/5
Y1 - 2019/5
N2 - Nasopharyngeal carcinoma (NPC) is endemic in southern China. Due to the unique anatomical and biological properties of NPCs, radiotherapy or combined modality based on radiotherapy is an effective treatment option. Helical tomotherapy (HT) is an emerging intensity modulated radiotherapy technology. The advantages of dose homogeneity, steepness of dose gradient, and protection of normal organs are reflected in the treatment of head and neck cancers. We present the preliminary (2-year) clinical outcomes of HT in 85 patients with locally advanced NPC (LA-NPC). Of these patients, 3 patients (3.5%) experienced treatment interruption due to severe pulmonary infection, and 82 (96.5%) completed radiation treatments. The 2-year estimate of progression-free survival, local relapse-free survival, nodal relapse-free survival, distant metastases-free survival, and overall survival rate were 90%, 96.3%, 98.8%, 96.3%, and 96.3%, respectively. Among the three patients that died, one had stage III disease and died from fatal nasopharyngeal bleeding after radiotherapy, while the other two patients succumbed to local recurrence. Our experience suggests that HT can achieve promising disease control and survival in the treatment of LA-NPC patients with mild acute and late toxicity profiles.
AB - Nasopharyngeal carcinoma (NPC) is endemic in southern China. Due to the unique anatomical and biological properties of NPCs, radiotherapy or combined modality based on radiotherapy is an effective treatment option. Helical tomotherapy (HT) is an emerging intensity modulated radiotherapy technology. The advantages of dose homogeneity, steepness of dose gradient, and protection of normal organs are reflected in the treatment of head and neck cancers. We present the preliminary (2-year) clinical outcomes of HT in 85 patients with locally advanced NPC (LA-NPC). Of these patients, 3 patients (3.5%) experienced treatment interruption due to severe pulmonary infection, and 82 (96.5%) completed radiation treatments. The 2-year estimate of progression-free survival, local relapse-free survival, nodal relapse-free survival, distant metastases-free survival, and overall survival rate were 90%, 96.3%, 98.8%, 96.3%, and 96.3%, respectively. Among the three patients that died, one had stage III disease and died from fatal nasopharyngeal bleeding after radiotherapy, while the other two patients succumbed to local recurrence. Our experience suggests that HT can achieve promising disease control and survival in the treatment of LA-NPC patients with mild acute and late toxicity profiles.
UR - http://www.scopus.com/inward/record.url?scp=85062855256&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062855256&partnerID=8YFLogxK
U2 - 10.1016/j.tranon.2019.02.011
DO - 10.1016/j.tranon.2019.02.011
M3 - Article
C2 - 30878894
AN - SCOPUS:85062855256
SN - 1936-5233
VL - 12
SP - 757
EP - 763
JO - Translational Oncology
JF - Translational Oncology
IS - 5
ER -